No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ROIV240621C12000
- 0.04
- -0.01-20.00%
15min DelayClose Jun 20 14:29 ET
0.04High0.03Low
0.03Open0.05Pre Close5 Volume11.74K Open Interest12.00Strike Price19.00Turnover144.08%IV11.48%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type0.1010Delta0.2047Gamma270.00Leverage Ratio-0.0400Theta0.0000Rho27.26Eff Leverage0.0011Vega
Intraday
- 5D
- Daily
News
Evaluating Roivant Sciences: Insights From 6 Financial Analysts
Roivant Sciences (NASDAQ:ROIV) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below provides a concise overview o
Express News | Cantor Fitzgerald Reiterates Overweight on Roivant Sciences
Roivant Sciences' (NASDAQ:ROIV) Performance Raises Some Questions
Even though Roivant Sciences Ltd. (NASDAQ:ROIV) posted strong earnings recently, the stock hasn't reacted in a large way. We decided to have a deeper look, and we believe that investors might be worr
Buy Rating Justified by Roivant Sciences' Growth Prospects and Strategic Pipeline Expansion
The Analyst Verdict: Roivant Sciences In The Eyes Of 6 Experts
6 analysts have shared their evaluations of Roivant Sciences (NASDAQ:ROIV) during the recent three months, expressing a mix of bullish and bearish perspectives.Summarizing their recent assessments, th
Piper Sandler Keeps Their Buy Rating on Roivant Sciences (ROIV)
Comments
» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
6
Morning Movers
Gapping up
$DoorDash(DASH.US$ stock rose 0.4% after CFRA Research upgraded its investment stance on the food delivery platform to buy from hold, citing its high growth potential.
$Roivant Sciences(ROIV.US$ stock rose 7.2% after the biotech said its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study.
Gapping down
$NIO Inc(NIO.US$ fell ...
Gapping up
$DoorDash(DASH.US$ stock rose 0.4% after CFRA Research upgraded its investment stance on the food delivery platform to buy from hold, citing its high growth potential.
$Roivant Sciences(ROIV.US$ stock rose 7.2% after the biotech said its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study.
Gapping down
$NIO Inc(NIO.US$ fell ...
22
$Pfizer(PFE.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$Vera Therapeutics(VERA.US$ Phase 2b
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$Akero Therapeutics(AKRO.US$ Phase 2b
$Spruce Biosciences(SPRB.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Annexon(ANNX.US$ Phase 2a
$Roivant Sciences(ROIV.US$...
$Leap Therapeutics(LPTX.US$ Phase 2
$Vera Therapeutics(VERA.US$ Phase 2b
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$Akero Therapeutics(AKRO.US$ Phase 2b
$Spruce Biosciences(SPRB.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Annexon(ANNX.US$ Phase 2a
$Roivant Sciences(ROIV.US$...
23
The sale of Roivant Sciences shares by an insider, without any recent insider buying, and a high insider ownership can signal mixed sentiments towards the company's future prospects. It could perpetuate caution among potential investors.
1
$Cellectar BioSciences(CLRB.US$ Phase 2
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2 ...
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2 ...
36
6
Read more